SEQUOIA: Zanubrutinib vs BR in First-Line CLL/SLL

The bispecific T-cell engager epcoritamab demonstrated favorable efficacy outcomes with manageable toxicities in patients treated in the expansion and optimization cohorts of the EPCORE CLL-1 trial.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Nicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Susan L. Slager, PhD, discussed the etiology and inherited genetic factors that are associated with the risk of chronic lymphocytic leukemia.

John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.